RekrutujeFaza III
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer…
Miasta: Białystok, Bydgoszcz, Gdynia, Koszalin i 6 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: ZakończoneNa świecie: RekrutujeFaza I/II
Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors
Miasta: GliwiceWiek: od 18 latSponsor: Pyxis Oncology Inc.
W Polsce: Rekrutacja wstrzymanaNa świecie: RekrutujeFaza III
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously…
Miasta: Bystra, Gdańsk, Kraków, Lublin i 7 innych miastWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza II/III
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Miasta: Bydgoszcz, Gdańsk, Gliwice, Katowice i 4 inne miastaWiek: od 18 latSponsor: Bicara Therapeutics Inc.
RekrutujeFaza I/II
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With…
Miasta: Białystok, Bydgoszcz, Gdańsk, Kielce i 2 inne miastaWiek: od 18 latSponsor: AbbVie Deutschland GmbH & Co. KG
RekrutujeFaza III
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Miasta: Gdańsk, Lublin, Poznań, Skórzewo i 2 inne miastaWiek: od 18 latSponsor: Summit Therapeutics Inc.
RekrutujeFaza III
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Miasta: Białystok, Gdańsk, Koszalin, Olsztyn i 5 innych miastWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels…
Miasta: Gdańsk, Gliwice, Lublin, Poznań i 2 inne miastaWiek: od 18 latSponsor: Pfizer Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic…
Miasta: Białystok, Kraków, Lublin, Poznań i 2 inne miastaWiek: od 18 latSponsor: Immunitybio Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Miasta: Gdańsk, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Miasta: Bielsko-Biala, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Daiichi Sankyo Inc.
RekrutujeFaza II/III
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Miasta: Białystok, Bydgoszcz, Gdańsk, Gliwice i 11 innych miastWiek: od 18 latSponsor: BioNTech SE
RekrutujeFaza III
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel…
Miasta: Gdańsk, Kraków, Warszawa, ŁódźWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza II/III
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No…
Miasta: Bydgoszcz, Gliwice, Szczecin, WrocławWiek: od 18 latSponsor: Rakuten Medical Inc.
RekrutujeFaza II/III
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Miasta: Gdańsk, Gliwice, Konin, Siedlce i 1 inne miastoWiek: od 0 latSponsor: Eikon Therapeutics Inc.
RekrutujeFaza III
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Miasta: Biała Podlaska, Białystok, Bydgoszcz, Bystra i 6 innych miastWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Miasta: Biała Podlaska, Białystok, Bydgoszcz, Bystra i 6 innych miastWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Miasta: Gdańsk, Kielce, Kraków, Olsztyn i 4 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer…
Miasta: Bydgoszcz, Konin, Koszalin, Poznań i 3 inne miastaWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza III
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle…
Miasta: Bydgoszcz, Poznań, WarszawaWiek: od 18 latSponsor: Ferring Pharmaceuticals
RekrutujeFaza III
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Miasta: Brzozów, Bydgoszcz, Gdańsk, Koszalin i 6 innych miastWiek: od 18 latSponsor: Shanghai Henlius Biotech Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC)…
Miasta: Białystok, Kielce, Otwock, Poznań i 3 inne miastaWiek: od 18 latSponsor: Bayer AG
RekrutujeFaza III
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Miasta: Białystok, Bydgoszcz, Gorlice, Grudziądz i 7 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Miasta: Białystok, Bydgoszcz, Gdynia, Gliwice i 5 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza I/II
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Miasta: Gdańsk, Gliwice, WarszawaWiek: od 18 latSponsor: Janssen Cilag International
RekrutujeFaza III
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable…
Miasta: Olsztyn, Poznań, Przemyśl, WarszawaWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1)…
Miasta: Gorlice, Kraków, Lublin, Olsztyn i 3 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC)…
Miasta: Białystok, Gdańsk, Kraków, Lublin i 6 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II/III
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Miasta: Gliwice, Konin, Piotrków TrybunalskiWiek: od 18 latSponsor: Inhibrx Biosciences Inc.
RekrutujeFaza III
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Miasta: Gdańsk, Kraków, WarszawaWiek: od 0 latSponsor: Replimune Inc.